Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.77 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.77 |
| ▸ | FNTA | P49354 | 7/20 | 0.56 |
| ▸ | FNTB | P49356 | 7/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366103 | 0.99 | CYP11B1 (0.79) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8303322 | 0.96 | CYP11B1 (0.72) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8302850 | 0.83 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL31472005 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL31471987 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL6409239 | 0.82 | CYP11B1 (0.54) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7259729 | 0.82 | CYP11B1 (0.61) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| Bromide SCHEMBL8005944 | 0.82 | CYP11B1 (0.56) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7163166 | 0.81 | CYP11B1 (0.55) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7194363 | 0.80 | CYP11B1 (0.57) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| US-6989383-B1 | Method of treating cancer | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-01-24 | — | — | US | disclosed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| EP-1019529-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-0891360-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6387903-B1 | ANTICANCER AGENT; CARDIOVASCULAR DISORDERS; VIRICIDES | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| WO-1997036900-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036583-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036593-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036881-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036890-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036889-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027854-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996037204-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B1 1/4885CYP11B2 6/4885FNTA 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.